Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

Show full item record



Permalink

http://hdl.handle.net/10138/300724

Citation

Garderet , L , Ziagkos , D , Van Biezen , A , Iacobelli , S , Finke , J , Maertens , J , Volin , L , Ljungman , P , Chevallier , P , Passweg , J , Schaap , N , Beelen , D , Nagler , A , Blaise , D , Poire , X , Yakoub-Agha , I , Lenhoff , S , Craddock , C , Schots , R , Rambaldi , A , Sanz , J , Jindra , P , Mufti , G J , Robin , M & Kroeger , N 2018 , ' Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion ' , Biology of Blood and Marrow Transplantation , vol. 24 , no. 3 , pp. 507-513 . https://doi.org/10.1016/j.bbmt.2017.11.017

Title: Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
Author: Garderet, Laurent; Ziagkos, Dimitris; Van Biezen, Anja; Iacobelli, Simona; Finke, Juergen; Maertens, Johan; Volin, Liisa; Ljungman, Per; Chevallier, Patrice; Passweg, Jakob; Schaap, Nicolaas; Beelen, Dietrich; Nagler, Arnon; Blaise, Didier; Poire, Xavier; Yakoub-Agha, Ibrahim; Lenhoff, Stig; Craddock, Charles; Schots, Rik; Rambaldi, Alessandro; Sanz, Jaime; Jindra, Pavel; Mufti, Ghulam J.; Robin, Marie; Kroeger, Nicolaus
Contributor: University of Helsinki, Clinicum
Date: 2018-03
Language: eng
Number of pages: 7
Belongs to series: Biology of Blood and Marrow Transplantation
ISSN: 1083-8791
URI: http://hdl.handle.net/10138/300724
Abstract: The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [al]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+. A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46% (95% CI, 38 to 54), whereas the estimated 4 year survival, relapse-free and overall, was 25% (95% CI, 18 to 33) and 30% (95% CI, 23 to 38), respectively. In a multivariate analysis patients with del (5q) and a blast excess displayed poorer survival (hazard ratio, 2.38; 95% CI, 1.44 to 3.93; P
Subject: MDS
del (5q)
Allogeneic stem cell transplantation
PROGNOSTIC SCORING SYSTEM
MARROW-TRANSPLANTATION
EUROPEAN-SOCIETY
TP53 MUTATIONS
WORKING PARTY
DEL(5Q)
LENALIDOMIDE
IMPACT
CHROMOSOME
BLOOD
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
pdf.pdf 663.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record